Precision BioSciences (NASDAQ:DTIL) is a clinical-stage biotechnology company focused on developing potentially curative genetic medicines through its proprietary ARCUS genome editing platform. Headquartered in Durham, North Carolina, the company leverages a naturally occurring endonuclease scaffold to engineer highly specific, versatile gene editors. ARCUS technology is designed to enable precise DNA modifications with a smaller molecular footprint than many competing systems, facilitating the development of off-the-shelf and in vivo gene therapies across multiple therapeutic areas.
The company’s pipeline encompasses both allogeneic cell therapies for oncology and in vivo treatments for genetic diseases. In oncology, Precision BioSciences is advancing allogeneic chimeric antigen receptor T-cell (CAR-T) candidates that are edited to reduce graft-versus-host reactions and enhance anti-tumor activity. For inherited disorders, the company is pursuing treatments for rare diseases caused by single-gene defects, aiming to correct or disable faulty genes directly in patients’ cells. Precision has also explored the application of ARCUS in areas such as infectious disease and agricultural biotechnology through research collaborations and licensing agreements.
Since its founding in 2006, Precision BioSciences has entered strategic partnerships to expand the reach of its genome editing platform. The company has collaborated with academic institutions and biopharmaceutical firms to accelerate the discovery and development of novel gene therapies. Over the years, Precision has built research and development facilities in both the United States and Europe to support process optimization, manufacturing scale-up and regulatory filings. These investments are intended to streamline the transition from early research to clinical proof-of-concept.
Under the leadership of President and Chief Executive Officer Matt Kane, Precision BioSciences maintains a management team with deep expertise in gene editing, cell therapy and biopharmaceutical operations. The company’s governance structure and scientific advisory boards feature recognized experts in molecular biology, immunology and regulatory affairs. By combining its proprietary technology with strategic alliances and a growing pipeline, Precision aims to bring transformative therapies to patients with high unmet medical needs around the world.
